Oct 19 2011 | News
Annual cancer tests are becoming a thing of the past. New guidelines out Wednesday for cervical cancer screening have experts at odds over some things, but they are united in the view that the common practice of getting a Pap test every year is too often and probably doing more harm than good.
|
Jun 17 2011 | News
ATLANTA (AP) —
The gap in cancer death rates between college graduates and those who only went
to high school is widening, the American Cancer Society reported Friday.
|
Jun 16 2011 | News
You're sitting in a freshly drywalled house, drinking coffee
from a plastic foam cup and talking on a cellphone. Which of these is most
likely to be a cancer risk?
|
Jan 19 2010 | News
MICHAEL FELBERBAUM AP Tobacco Writer RICHMOND, Va. (AP) — The Food and Drug Administration is working to lift the smokescreen clouding the ingredients used in cigarettes and other tobacco products.
|
Jan 19 2010 | News
LAURAN NEERGAARD AP Medical Writer WASHINGTON (AP) — Just as millions head to tanning beds to prepare for spring break, the Food and Drug Administration will be debating how to toughen warnings that those sunlamps pose a cancer risk. Yes, sunburns are particularly dangerous.
|
Oct 15 2009 | News
Radient Pharmaceuticals Corporation, a US-based pharmaceutical company, announced today it has entered into a collaboration agreement through its wholly owned subsidiary AMDL Diagnostics, Inc.
|
Oct 7 2009 | News
VICTOR EPSTEIN Associated Press Writer PARAMUS, N.J. (AP) — A northern New Jersey lawmaker wants to extend current limits on the availability of tobacco cigarettes to apply to electronic cigarettes to prevent them from being embraced by children.
|
Aug 20 2009 | News
MIKE STOBBE AP Medical Writer ATLANTA (AP) — Four years after the government severely restricted its use, the lung cancer drug Iressa may be poised to make a comeback: A study concludes it can slow the deadly disease better than standard chemotherapy in certain patients.
|
Aug 3 2009 | News
Genentech, Inc., a wholly-owned member of the Roche Group, today announced that the FDA approved Avastin(R) (bevacizumab) plus interferon-alfa for people with metastatic renal cell carcinoma, the most common type of kidney cancer.
|
Apr 28 2009 | News
MARILYNN MARCHIONE AP Medical Writer CHICAGO (AP) — An experimental treatment added four months to the lives of men with advanced prostate cancer in a study that tested an entirely new approach to fighting the disease, doctors reported Tuesday. Dendreon Corp.
|